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The majority of biological processes are controlled and regulated
by an intricate network of thousands of interacting proteins.
Identifying and understanding the key components of these
protein networks, especially those that play a critical role in
disease, is a challenge that promises to dramatically alter our
current approach to healthcare. To facilitate this process,
we have developed a method for the rapid construction of a
chromosomally integrated, bacterial reverse two-hybrid system
(RTHS) that enables the identiﬁcation of interacting protein
partners. Chromosomal integration of the RTHS enables stable
protein expression, free of plasmid copy-number eﬀects, as well
as eliminating false positives arising from plasmid ejection. We
have utilized this approach to identify the interactions used by
the inﬂuenza virus NS1 protein to silence the host’s antiviral
defences.
Mammalian cells contain several proteins dedicated to detecting
and responding to viral infection. The RNA helicase, retinoic
acid inducible gene-I (RIG-I), acts as the sensor for inﬂuenza
and other negative strand RNA viruses. Upon detection of
viral RNA, the innate immune response is characterized by the
rapid production of a range of cytokines, most prominently
type I interferon (IFN-a/b),1 which act to reduce viral replication
and spread.2 RIG-I is a 106 kDa protein that consists of
3 functional domains (Fig. 1).3–5 The N-terminal region
contains two caspase activation and recruitment domains
(CARD) that interact with the downstream eﬀectors of
RIG-I and activate interferon production. The ﬁrst CARD
was recently shown to bind the E3 ubiquitin ligase, tripartite
motif protein 25 (TRIM25), facilitating the ubiquitination of
the second CARD at Lys172 (an essential modiﬁcation for
IFN induction).6 The central domain of RIG-I is the
DExH box RNA helicase/adenosine triphosphatase domain
(helicase), and is thought to be responsible for unwinding the
viral genome.7 The C-terminal regulatory domain (RD)
recognises and binds viral RNA. In the absence of viral
RNA, RD interacts with CARD to keep RIG-I in a closed
conformation, preventing signalling. Upon detection of viral
RNA by RD, RIG-I undergoes a change in conformation
to expose CARD,3 activating the cascade of downstream
eﬀectors that initiate the production of type I interferon.8,9
Viruses have evolved multiple mechanisms to inactivate the
viral sensors of the host.10 In the case of inﬂuenza virus, the
26 kDa non-structural protein 1 (NS1) is widely regarded as a
factor that antagonizes the host’s immune responses;11,12 NS1
deﬁcient viruses are highly attenuated and only replicate
eﬃciently in IFN-deﬁcient systems.13 NS1 function relies on
its ability to participate in a multitude of protein–protein and
protein–RNA interactions, and although RIG-I is known to
be targeted by NS1,13 the exact nature of their interaction is
unclear. NS1 has been shown to co-precipitate with RIG-I
indicating a direct interaction between the two proteins, but it
has been suggested that the interaction may be mediated
by a third factor.1 The recent identiﬁcation of TRIM25
as a binding partner of NS1 has resulted in an alternative
hypothesis for the mechanism of NS1 inactivation of RIG-I,
where the NS1–TRIM25 interaction inhibits TRIM25
multimerization, therefore preventing the ubiquitination of
RIG-I CARD, suppressing RIG-I signal transduction and
ultimately IFN production.6
To enable the facile probing of these (and other)
protein–protein interactions, we constructed a two-plasmid
system (an integration vector and a helper plasmid) that allows
the rapid assembly of a chromosomally integrated, bacterial
RTHS (Fig. 2). The RTHS has been previously reported,14,15
and is based on the bacteriophage regulatory system, linking
the disruption of the interaction between the two targeted
proteins, expressed as hybrid fusions of a chimeric repressor
complex (434 and P22), to the expression of three reporter
genes. The reporter construct (present on the chromosome of
the host strain SNS126)14 includes the chimeric 434/P22
operators followed by HIS3 (imidazole glycerol phosphate
dehydratase) and KanR (aminoglycoside 30-phosphotransferase
for kanamycin resistance) genes. SNS126 lacks the native
Fig. 1 The domains of RIG-I. The N-terminus of RIG-I contains two
CARDs (residues 1–176), followed by a linker region, and helicase
(residues 239–793). The C-terminus of the protein (residues 793–925)
contains the regulatory domain (RD).
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HISB gene and requires expression of the yeast HIS3 gene for
histidine biosynthesis. The stringency of both reporter genes is
chemically tuneable (with 3-amino-1,2,4-triazole and kanamycin),
and both gene products are required for host survival on
selective media. The third reporter gene, LacZ encodes
b-galactosidase and is used to quantify the targeted protein–
protein interaction through o-nitrophenyl-b-galactoside (ONPG)
assays.
The integration vector encodes the bacteriophage 434
repressor DNA binding domain, and a chimeric P22 variant
of 434 (from pTHCP14)14 each followed by a polylinker for
insertion of the targeted proteins (Fig. 3). The plasmid also
contains a conditional g replication origin of R6K, and an
HK022 phage attachment site (both from pAH68).16 The R6K
origin requires the trans-acting II protein (encoded by pir) for
plasmid replication, enabling its over-expression during
cloning in pir+ strains of DH5a E. coli (DH5a-pir). As the
plasmid is not replicated in SNS126 (non-pir), integrants are
distinguishable from transformants. Integration of pTH-INT
into the HK022 attachment site of SNS126 occurs in the
presence of the HK022 integrase, whose expression from the
helper plasmid (pAH69T) is controlled by cI857,17 and is
induced at elevated temperatures. The helper plasmid is a
derivative of pAH69,16 with BLA (ampicillin resistance)
replaced with TETA (tetracycline resistance) to enable selection
for integrants containing pTH-INT.
We used this system to determine the protein–protein inter-
actions that are utilized by Inﬂuenza A NS1 to silence the
host’s viral sensors. We reasoned that the absence of
direct homologues of the human viral sensor pathway
proteins in bacteria would minimise the possibility of native
proteins inadvertently mediating the interaction of NS1 with
RIG-I/TRIM25 and leading to false-positive data. As all the
target proteins are routinely over-expressed in E. coli, we were
conﬁdent that they would express and fold correctly in our
bacterial RTHS, reducing the likelihood of false-negatives.
The gene encoding Inﬂuenza A NS1 was cloned into the
pTH-INT plasmid as an N-terminal fusion with 434, while
RIG-I or TRIM25 was cloned as an N-terminal fusion
with P22. The resulting plasmids were integrated into the
chromosome of the RTHS strain (SNS126) by phage-speciﬁc
recombination using the HK022 phage integrase, as previously
described.16 The resulting RTHS strains (NS1–RIG-I and
NS1–TRIM25) and a negative control strain expressing only
434 and P22 were used to determine and quantify the extent of
each protein–protein interaction. We used a previously built
RTHS as the positive control.18 Upon addition of IPTG, the
targeted proteins are expressed as fusions with 434 or P22,
from the chromosomally integrated pTH-INT cassette. The
interaction of the IPTG-induced proteins reconstitutes a
functional repressor that prevents transcription of reporter
genes downstream (Fig. 2A). If the target proteins do not
interact, the host cells will express the reporter genes regardless
Fig. 2 Monitoring protein–protein interactions with a bacterial reverse two-hybrid system. (A) If the targeted proteins interact (NS1, and
X = RIG-I, CARD, helicase, RD or TRIM25) a functional repressor will be reconstituted that prevents the transcription of the reporter genes
downstream. This will lead to cell death on selective media. (B) If the targeted proteins do not interact, the 434.P22 repressor is not functional,
allowing the transcription of the reporter genes. This will lead to growth on selective media.
Fig. 3 The RTHS plasmid pTH-INT. The plasmid includes two
multiple cloning sites used for the cloning of the targeted proteins
into the RTHS. Protein expression is controlled via a pTac promoter,
with a copy of LacIq included to enable stringent IPTG induction of
the RTHS proteins. The plasmid also contains an HK022 phage
attachment site (attHK022), and a P6K replication origin (oriR).
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of IPTG levels (Fig. 2B). We quantiﬁed the protein–protein
interaction of each NS1 RTHS using o-nitrophenyl-b-galacto-
side (ONPG) assays. The data (Fig. 4) indicated an interaction
between NS1 and TRIM25 (reduction in LacZ gene product as
IPTG levels increased), in agreement with the recently
reported co-immunoprecipitation studies.6 We also observed
a direct interaction between NS1 and RIG-I, which the data
suggested is weaker than that between NS1 and TRIM25. The
lower aﬃnity may be an artefact of the RTHS and a conse-
quence of the larger size of RIG-I (compared to TRIM25)
preventing the optimal interaction of the 434 and P22 repressor
domains. We identiﬁed the domains of RIG-I that are bound
byNS1 by constructing RTHS for theNS1–CARD,NS1–helicase
and NS1–RD. The ONPG assays of the resulting RTHS
strains (Fig. 4) identiﬁed CARD and RD as the domains of
RIG-I that are targeted by NS1.
We visualized the targeted protein–protein interactions by
drop spotting ten-fold serial dilutions of the above NS1 RTHS
strains (with positive and negative controls) onto selective
media containing 3-amino-1,2,4-triazole (2.5 mM) and
kanamycin (25 mg mL1) in the absence or presence of IPTG
(100 mM). The drop spotting data (Fig. 5) conﬁrmed the
interaction between NS1–RIG, NS1–CARD, NS1–RD and
NS1–TRIM25, correlating with the above ONPG assays. To
eliminate the possibility that the observed growth inhibition is
due to the toxicity of the expressed proteins, the RTHS
strains were drop spotted onto rich media (LB agar) with
100 mM IPTG. All strains grew normally under these conditions
(ESIw); the observed growth inhibition on selective media
can therefore be attributed to the targeted protein–protein
interactions.
In summary, we have developed a method for the rapid
construction of bacterial RTHS and have used this approach
to identify the direct interaction of NS1 with RIG-I, by
binding to its CARD and RD domains. These observations
(when combined with currently available data) suggest that
NS1 binds to RIG-I in its closed conformation, in which the
RD and CARD domains are known to be in close proximity.
Such an interaction would stabilize the closed conﬁrmation of
RIG-I, masking its viral genome recognition site and preventing
the conformational change to the active form. The ability of
NS1 to bind CARD also suggests that the viral protein may
additionally bind the active form of RIG-I, directly interfering
with its subsequent downstream signalling. Our data also
conﬁrm the interaction of NS1 with TRIM25 that was
previously reported.6 These observations taken together lead
us to suggest that the postulated mechanisms for NS1 inhibition
of RIG-I are not mutually exclusive, and that NS1 targets the
antiviral RIG-I signaling pathway at multiple points through
its interaction with TRIM25, CARD and RD, demonstrating
the robust manner in which Inﬂuenza A NS1 silences the
host’s antiviral sensors. The reported two-plasmid system may
also be used to probe other protein–protein interactions,
however (to avoid false positives) the expression of functional
target proteins in bacteria should be conﬁrmed prior to
constructing the RTHS. We are currently using the above
Fig. 4 ONPG assay. The targeted protein–protein interactions of NS1 were quantiﬁed using ONPG assays. IPTG increases cellular levels of the
targeted proteins (expressed as fusions with 434 or P22 repressor domains, see Fig. 2), leading to reduced expression and eventual shutdown of the
LacZ reporter gene. b-galactosidase levels (LacZ gene product) are monitored by ONPG assays. The data indicate an interaction between NS1 and
RD, TRIM25 and CARD, and no interaction between NS1 and helicase.
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NS1 RTHS in high-throughput screens to identify compounds
that disrupt these critical protein–protein interactions, for use
as chemical tools to allow the role of each of these interactions
to be deciphered in cells.
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